蓝帆医疗(002382) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast The company projects a net loss attributable to shareholders of CNY 100-150 million for H1 2025, a narrowed loss year-over-year, while non-GAAP net loss is expected to widen 2025 Semi-Annual Performance Forecast | Item | Current Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | Net Income Attributable to Shareholders (CNY millions) | Loss: 100 – 150 | Loss: 160.22 | | Year-over-Year Change (%) | Growth: 6.38 - 37.58 | - | | Net Income Excluding Non-Recurring Items (CNY millions) | Loss: 170 – 230 | Loss: 196.40 | | Year-over-Year Change (%) | Change: -17.11 - 13.44 | - | | Basic Earnings Per Share (CNY/share) | Loss: 0.10 – 0.15 | Loss: 0.16 | Communication with Accounting Firm The company has pre-communicated with its accounting firm regarding the performance forecast, with no significant disagreements, though the forecast remains unaudited - The financial data in this performance forecast is unaudited by the accounting firm, but the company has pre-communicated with them on relevant matters, with no significant disagreements[4] Explanation of Performance Changes H1 2025 performance fluctuations are primarily due to fair value changes in an associate, improved cardiovascular business performance, non-cash financial expenses, and losses in the health protection segment Fair Value Changes of Associate Company The company recognized a non-cash fair value loss of approximately CNY 120 million due to valuation changes in associate Suzhou Tongxin Medical following its pre-IPO financing - The company recognized a non-cash fair value loss of approximately CNY 120 million due to valuation changes in associate Suzhou Tongxin Medical Technology Co., Ltd. following its pre-IPO financing[5] - As of now, the company, through its subsidiary Shandong Jiwei Medical Products Co., Ltd., still holds 4.88% equity in Suzhou Tongxin[5] Improved Performance of Cardiovascular and Cerebrovascular Business Unit Excluding non-operating impacts, the Cardiovascular and Cerebrovascular Business Unit's H1 2025 sales revenue grew over 20%, achieving profitability and significant profit contribution - The Cardiovascular and Cerebrovascular Business Unit's H1 2025 sales revenue exceeded CNY 690 million, representing over 20% year-over-year growth[5] - Benefiting from new product ramp-up and reduced expense ratios, this business unit has achieved profitability at the operating level[5] Financial Expenses and Headquarters Overhead Due to potential repurchase obligations from a 2024 subsidiary strategic investment, the company recognized a non-cash financial expense of CNY 25 million in Q2 2025 - Due to a CNY 1 billion strategic investment in a subsidiary in 2024, its potential repurchase obligation was recognized as a financial liability, resulting in a CNY 25 million non-cash financial expense in Q2 2025[6] Performance Fluctuations of Health Protection Business Unit The Health Protection Business Unit experienced a loss in Q2 2025 due to fluctuating overseas orders and pricing pressure - The Health Protection Business Unit incurred losses in Q2 2025 due to fluctuations in overseas orders and sales price pressure[6] Other Relevant Information The company emphasizes this performance forecast is preliminary, with final data subject to the official semi-annual report, advising investors of associated risks - This performance forecast represents preliminary estimates by the company's finance department, with final data subject to the officially disclosed semi-annual report[7] - The company's designated information disclosure media include China Securities Journal, Shanghai Securities News, Securities Times, Securities Daily, and Juchao Information Network[7]